26
Participants
Start Date
November 23, 2017
Primary Completion Date
February 18, 2021
Study Completion Date
August 21, 2024
Varlilumab
"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).~Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
The Christie NHS Foundation Trust, Manchester
Oxford University Hospitals NHS Foundation Trust, Oxford
Plymouth Hospitals NHS Trust, Plymouth
University Hospital Southampton NHS Foundation Trust, Southampton
Collaborators (2)
University Hospital Plymouth NHS Trust
OTHER
The Christie NHS Foundation Trust
OTHER
Oxford University Hospitals NHS Trust
OTHER
Celldex Therapeutics
INDUSTRY
Cancer Research UK
OTHER
University Hospital Southampton NHS Foundation Trust
OTHER